In Regard to Shortall et al

Disclosures: M.R.S. discloses research grants and drug costs or biomarker testing costs (all to the institution and all active in the past 36 months, but on research outside this research) from Astellas, Clovis Oncology, Janssen, Pfizer, Novartis, and Sanofi-Aventis; speaker fees at clinical trial statistics training meeting for clinicians (no discussion of particular drugs) from Lilly Oncology and Janssen; and independent membership of many independent data monitoring committees, but all for academic sponsors and none paid. E.H. discloses a Cancer Research UK E. Hall grant for Clinical Trials Project Grant to host the institution to support central trial running costs; Clinical Trials Unit programmatic grant funding to host institution to provide core support; a grant from Accuray for the central trial management of a radiation therapy trial in prostate cancer; a grant from Varian Medical Systems to support the central trial management of a radiation therapy trial in prostate cancer; a grant from Astra Zeneca to support central trial costs for academic trials in prostate cancer; provision of study drug and placebo from Astra Zeneca; a grant from Janssen-Cilag to support trial health economic evaluation in an academic trial in prostate cancer; a grant from Bayer to support central trial costs for an academic trial in prostate cancer; and grant from Merck Sharp and Dohm to support central trial costs for an academic trial in prostate cancer. D.P.D. discloses Cancer Research UK Programme Grants C46/A2131 (1999-2004), C46/A3976 (2004-2009), C46/A10588 (2009-14), C33589/A19727 (2015-19) from the Institute of Cancer Research; a share of royalty income abiraterone through the ICR's Rewards to Discoverer's Scheme and a location and stabilization device (European Patent issued EP1933709B1; pending in Canada and India); and consultancy fees from Jansen Advisory Boards (2015-2021).